A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Phase 1

Completed

• Conditions: Healthy Volunteers
• Interventions: Drug: ACP-196; Drug: Moxifloxacin 400 mg; Drug: Placebo

• Registration Number: NCT04867980
• Lead Sponsor: Acerta Pharma BV

Brief Summary

This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).

Detailed Description

This is a single-dose, randomized, double-blind, double-dummy, placebo- and positive-controlled, 4-period, balanced crossover study under fasting conditions. Participants will be randomized to 1 of 4 treatment sequences: ABCD, BDAC, CADB, or DCBA. On 4 different occasions (4 periods), each participant will receive Treatment A (a single therapeutic oral dose of 100 mg ACP-196), Treatment B (a single supratherapeutic oral dose of 400 mg ACP-196), Treatment C (a single oral dose of 400 mg moxifloxacin) or Treatment D (a single oral dose of ACP-196 and moxifloxacin matching placebos) according to a randomization scheme. The washout period will be \>= 5 days between each dose. The clinic attempted to contact participants using their standard procedures approximately 14 days after the last study drug (or placebo) administration to determine if any adverse events (AEs) had occurred since the last dose of study drug(s). An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Study Timeline

• Study Start: 2016-04-01
• Primary Completion: 2016-05-09
• Study Completion: 2016-05-09
• Status Verified: 2021-04
• Study First Submitted: 2021-04-28
• Study First Submitted QC: 2021-04-28
• Last Update Submitted: 2021-04-28
• Study First Posted: 2021-04-30
• Last Update Posted: 2021-04-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Continuous non-smoker participant who has not used nicotine-containing products for >= 3 months before the first dose
• Have body mass index of >= 18.0 and <= 32.0 kg/m^2 at screening
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiograms (ECGs), as deemed by the principal investigator (PI)
• No clinically significant history or presence of ECG findings as judged by the PI or qualified designee at screening and each check-in, including each criterion as: 1) Normal sinus rhythm (heart rate between 50 and 100 beats per minute [bpm]), 2) QTcF interval ≤ 450 milliseconds (msec), 3) QRS interval ≤ 110 msec, and 4) PR interval ≤ 220 msec
• Women participants must be of non-childbearing status
• Women participants must have negative serum pregnancy test
• ability to swallow multiple capsules and/or tablets using size 0 blank capsules (up to a maximum of 5 capsules per participant)
• Male participants must be willing to use protocol specified contraception methods

Read More

Exclusion Criteria

• Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
• History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study
• Presence of any clinically significant, ongoing systemic bacterial, fungal, or viral infections (including upper respiratory tract infections, but excluding localized cutaneous fungal infections), in the opinion of the PI
• History of any major surgical procedure within 30 days before the first dose of study drug
• History or presence of alcoholism or drug abuse within the past 2 years before screening
• Any clinically significant condition that may affect ACP-196 absorption in the opinion of the PI, including gastric restrictions and bariatric surgery (eg, gastric bypass).
• Allergy to band-aids, adhesive dressing, or medical tape
• History or presence of clinically significant thyroid disease
• Prior exposure to Bruton's tyrosine kinase inhibitors (eg, ACP-196, ibrutinib) within 3 months before the first dose of study drug
• Positive urine cotinine at screening
• Positive urine drug or alcohol results at screening or each check-in
• Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at screening
• Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening
• Seated heart rate is lower than 50 bpm or higher than 99 bpm at screening
• Unable to refrain from or anticipates the use of protocol defined medications for 28 days before the first dose of study drug and throughout the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
ABCD	Moxifloxacin 400 mg	Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be \>= 5 days between each dose.
CADB	Moxifloxacin 400 mg	Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be \>= 5 days between each dose.
CADB	ACP-196	Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be \>= 5 days between each dose.
BDAC	ACP-196	Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be \>= 5 days between each dose.
ABCD	Placebo	Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be \>= 5 days between each dose.
BDAC	Placebo	Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be \>= 5 days between each dose.
CADB	Placebo	Participant will receive a single oral dose of 4 study treatments with the sequences of CADB. The washout period will be \>= 5 days between each dose.
DCBA	ACP-196	Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be \>= 5 days between each dose.
DCBA	Moxifloxacin 400 mg	Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be \>= 5 days between each dose.
DCBA	Placebo	Participant will receive a single oral dose of 4 study treatments with the sequences of DCBA. The washout period will be \>= 5 days between each dose.
ABCD	ACP-196	Participant will receive a single oral dose of 4 study treatments with the sequences of ABCD. The washout period will be \>= 5 days between each dose.
BDAC	Moxifloxacin 400 mg	Participant will receive a single oral dose of 4 study treatments with the sequences of BDAC. The washout period will be \>= 5 days between each dose.

Primary Outcome Measures

Name	Time	Method
The QTcF Change From Baseline at Postdose Timepoints (dQTcF)	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period

Secondary Outcome Measures

Name	Time	Method
Incidence of Abnormal Vital Signs and Physical Examinations Reported as TEAEs	From Day 1 through 24 hours after the last dose of study drug of the last period (approximately 1 month and 8 days)
Incidence of Abnormal ECGs Reported as TEAEs	From Day 1 through 24 hours after the last dose of study drug of the last period (approximately 1 month and 8 days)
Change in Time-matched QTcF Interval Following Moxifloxicin Administration Compared With Matching Placebo	1, 2, 3, and 4 hour post moxifloxicin dose in each period
Change From Baseline in Heart Rate at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Change From Baseline in PR Interval at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Change From Baseline in RR Interval at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Change From Baseline in QRS Interval at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Change From Baseline in QT Interval at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Number of Participants With Nonspecific T Waves Abnormality at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Number of Participants With Nonspecific U Waves Abnormality at Postdose Time Points	0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Percent of AUC0-inf Extrapolated (AUC%extrap) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Maximum Measured Plasma Concentration (Cmax) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Time of the Maximum Measured Plasma Concentration (Tmax) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Apparent Terminal Elimination Rate Constant (λz) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Apparent Terminal Elimination Half-life ( t½) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Apparent Total Plasma Clearance (CL/F) of ACP-196	-0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period
Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious AEs (TESAEs)	From Day 1 through 14 days after the last dose of study drug of the last period (approximately 1 month and 8 days)
Incidence of Abnormal Clinical Laboratory Parameters Reported as TEAEs	From Day 1 through 24 hours after the last dose of study drug of the last period (approximately 1 month and 8 days)

Trial Locations

Locations (1)

Celerion; 🇺🇸 Tempe, Arizona, United States